INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Rhea-AI Summary

INmune Bio (NASDAQ: INMB) will present two scientific posters at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) in San Diego on Dec 1–4, 2025. The company will present Phase 2 MINDFuL results for XPro1595 (a selective soluble TNF neutralizer) during a session running from 3:30 PM Dec 1 to 5:30 PM Dec 2 PT at location P057 with presenting author Kim A. Staats, PhD. A second presentation, led by Sarah Barnum, PhD of Cognition Metrics, will report validation work on the Early Mild Alzheimer’s Cognitive Composite (EMACC) and its associations with blood biomarkers on Dec 4, 2025 at location P316.

Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.

Presentations:

Title:	XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial
Date:	Monday, December 1, until Tuesday December 2, 2025
Time:	3:30pm (December 1st) – 5:30pm (December 2nd) PT
Location:	P057
Presenting author:	Kim A. Staats, PhD. INmune Bio.
Title:	Validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer’s Disease
Date:	Thursday, December 4, 2025
Time:	7:15am - 5:00pm PT
Location:	P316
Presenting author:	Sarah Barnum, PhD. Cognition Metrics.

About INmune Bio Inc.

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target immunology and inflammation. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. The second program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. The third program, INKmune®, is designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer and is currently in a trial in metastatic castration-resistance prostate cancer.  To learn more, please visit www.inmunebio.com.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including the results of the Phase 2 MINDFuL trial, the timing of key milestones, future plans or expectations for the treatment of XPro™, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com

Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com

FAQ

When will INmune Bio (INMB) present XPro1595 Phase 2 MINDFuL results at CTAD 2025?

The XPro1595 MINDFuL results are scheduled during a session from 3:30 PM Dec 1 to 5:30 PM Dec 2, 2025 PT at location P057.

What is the title of INmune Bio's poster on Dec 4, 2025 at CTAD and who presents it?

The Dec 4 poster is "Validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer’s Disease", presented by Sarah Barnum, PhD at location P316.

Where and when is the 18th CTAD conference where INMB is presenting?

CTAD 2025 takes place in San Diego, CA from December 1–4, 2025.

Who is the presenting author for INmune Bio's XPro1595 poster at CTAD 2025?

The XPro1595 poster is presented by Kim A. Staats, PhD representing INmune Bio at location P057.

What topics will INmune Bio and collaborators cover in their CTAD 2025 presentations?

Presentations cover XPro1595 Phase 2 MINDFuL results in early Alzheimer’s with inflammation and EMACC validation linked to blood-based Alzheimer’s biomarkers.